Bayer Regeneron Eye Drug Meets Study Goal
By wchung | 23 Jun, 2026
Regeneron Pharmaceuticals Inc. and Bayer HealthCare AG said Thursday their developing VEGF Trap-Eye drug met key vision improvement goals in a midstage study.
The drug is aimed at improving vision in patients with diabetic macular edema. The condition is a disease of the retina that affects individuals with diabetes and can lead to blindness.
The study, which took place over 24 weeks, compared VEGF Trap-Eye with laser therapy.
The companies also said VEGF Trap-Eye was well tolerated, and there were no drug-related serious adverse events.
Shares of Regeneron, which is based in Tarrytown, N.Y., closed at $30.46 Wednesday. Bayer HealthCare AG is based in Germany.
2/18/2010 8:18 AM NEW YORK (AP)
© 2026 by Asian Media Group Inc.
Recent Articles
- Oil Prices Extend Decline on Smoother Crude Flows via Hormuz
- Anthropic's Mythos Took Only Hours to Find Weaknesses in Every Classified US Government System
- How SK Hynix's Bet on a Niche Memory Chip Made It More Valuable Than Samsung
- US on Track to Break World Cup Attendance Record Despite High Ticket Prices
- S. Korea Coach Warns Team Against Complacency Before South Africa Match
- Senate Joins House to Require Trump to Seek Approval for Iran Hostilities
- US Consumers Favor Homebuying over Renting for First Time Since 2023
- US Manufacturing Rises but Factory Employment Falls to Six-Year Low
- Meta Launches Cheaper AI Smart Glasses Starting at $299
- How the Philippines Went from an Asian Economic Leader to Laggard